Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis
申请人:SANKYO COMPANY LIMITED
公开号:EP0844000A1
公开(公告)日:1998-05-27
Compounds of formula (I):
[wherein: R1 is aryl; R2 is hydrogen, alkyl, alkoxy, halogen or cyano; R3 is a group of formula -B-NR4R5, where R4 and R5 are independently hydrogen, alkyl or substituted alkyl or R4 and R5, together with the nitrogen to which they are attached, form a heterocycle, and B is alkylene or a group of formula -CH2CH(OR6)CH2-, where R6 is hydrogen, alkanoyl, substituted alkanoyl or arylcarbonyl, or a group of formula -D-R7, where D is a single bond or alkylene and R7 is a heterocycle; and A is alkylene; and pharmaceutically acceptable salts and esters thereof] are useful for the treatment and prevention of psychosis.
式(I)化合物:
其中R1 是芳基;R2 是氢、烷基、烷氧基、卤素或氰基;R3 是式-B-NR4R5 的基团,其中 R4 和 R5 独立地是氢、烷基或取代的烷基,或 R4 和 R5 与它们所连接的氮一起构成杂环,B 是亚烷基或式-CH2CH(OR6)CH2-的基团,其中 R6 是氢、烷酰基、取代的烷酰基或芳羰基,或式-D-R7 的基团,其中 D 是单键或亚烷基,R7 是杂环;和 A 是亚烷基;及其药学上可接受的盐和酯]可用于治疗和预防精神病。